May 14, 2026 10:55AM
May 14, 2026 10:55AM
Feb 24, 2026 10:17AM
Dec 16, 2025 04:06PM
Dec 16, 2025 04:05PM
Nov 9, 2025 06:07PM
Nov 9, 2025 06:07PM Vir Biotechnology Announces AASLD The Liver MeetingĀ® Presentation & New England Journal of Medicine Publication of Phase 2 Data Demonstrating Tobevibart & Elebsiran Combination Deliver High R
Nov 3, 2025 10:01AM
Nov 3, 2025 08:00AM
Aug 6, 2025 04:05PM
Aug 6, 2025 08:06AM
Aug 6, 2025 08:05AM
Jul 31, 2025 08:06AM
Jul 31, 2025 08:05AM Vir Biotechnology Initiates Second Pivotal Trial in Its Global ECLIPSE Registrational Program for Chronic Hepatitis Delta
May 7, 2025 04:05PM
Mar 21, 2025 07:10AM
Mar 13, 2025 08:05AM
Feb 26, 2025 04:05PM
Dec 12, 2024 04:07PM
Dec 12, 2024 04:05PM
Nov 18, 2024 09:15PM Vir Biotechnology Presents Positive Chronic Hepatitis Delta Clinical Trial Data and Announces Initiation of Phase 3 Registrational Program
Nov 18, 2024 04:06PM
Nov 18, 2024 04:05PM
Oct 31, 2024 04:05PM
Sep 4, 2024 08:30AM
Aug 20, 2024 06:45AM
Aug 1, 2024 04:02PM
Jun 26, 2024 08:05AM Vir Biotechnology (VIR) Receives FDA IND Clearance and Fast Track Designation for Tobevibart and Elebsiran for the Treatment of Chronic Hepatitis Delta Infection
Jun 26, 2024 08:05AM
Jun 5, 2024 02:37PM
Jul 5, 2023 07:18PM
Mar 24, 2023 01:18AM
Nov 16, 2022 08:30AM
Nov 16, 2022 08:30AM
Nov 3, 2022 04:03PM Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2022 Financial Results
Nov 3, 2022 04:03PM
Aug 23, 2022 07:30PM
Aug 9, 2022 04:02PM
Aug 9, 2022 04:02PM
May 6, 2022 06:47AM
May 5, 2022 04:07PM
May 5, 2022 04:07PM Vir Biotechnology Provides Corporate Update and ReportsĀ First Quarter 2022 Financial Results
Apr 5, 2022 05:37PM
Apr 5, 2022 01:56PM
Mar 28, 2022 09:15AM
Mar 28, 2022 06:57AM
Mar 28, 2022 06:57AM
Mar 25, 2022 04:05PM
Mar 25, 2022 04:04PM US Food and Drug Administration Revises Emergency Use Authorization for Sotrovimab Due to Omicron BA.2 Subvariant
Mar 25, 2022 04:04PM

323,325 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All